PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation | Zendy

Sheetal Bodhankar | Zendy; Yingxin Chen | Zendy; Andrew Lapato | Zendy; Abby L. Dotson | Zendy; Jianming Wang | Zendy; Arthur A. Vandenbark | Zendy; Julie A. Saugstad | Zendy; Halina Offner | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

PD-L1 Monoclonal Antibody Treats Ischemic Stroke by Controlling Central Nervous System Inflammation

Author(s) -

Sheetal Bodhankar,

Yingxin Chen,

Andrew Lapato,

Abby L. Dotson,

Jianming Wang,

Arthur A. Vandenbark,

Julie A. Saugstad,

Halina Offner

Publication year - 2015

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.115.010592

Subject(s) - medicine , monoclonal antibody , central nervous system , inflammation , ischemic stroke , stroke (engine) , antibody , immunology , pathology , ischemia , cardiology , mechanical engineering , engineering

Both pathogenic and regulatory immune processes are involved in the middle cerebral artery occlusion (MCAO) model of experimental stroke, including interactions involving the programmed death 1 (PD-1) receptor and its 2 ligands, PD-L1 and PD-L2. Although PD-1 reduced stroke severity, PD-L1 and PD-L2 appeared to play pathogenic roles, suggesting the use of anti-PD-L monoclonal antibody therapy for MCAO.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research